



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade:	10.00
Trade Time:	12:53 PM ET Jul 25, 2017
Change:	-0.65 (-6.103%)
Day Range	9.85 - 10.80
52-Week Range	3.20 - 17.50
Volume	1,958,019

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 2, 2017*
[Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA\(R\) \(pembrolizumab\) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy](#)
- May 19, 2017*
[Dynavax to Present Data on SD-101 in Combination with KEYTRUDA\(R\) at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- May 8, 2017*
[Dynavax Reports First Quarter 2017 Financial Results](#)
- Apr 3, 2017*
[Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B](#)
- Mar 20, 2017*
[Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Jul 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)